VINKLEROVÁ, Petra, Petra OVESNÁ, Markéta BEDNAŘÍKOVÁ, Luboš MINÁŘ, Michal FELSINGER, Jitka HAUSNEROVÁ a Vít WEINBERGER. Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis? Cancers. Basel: MDPI, 2022, roč. 14, č. 1, s. 1-11. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers14010115.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?
Autoři VINKLEROVÁ, Petra (203 Česká republika, domácí), Petra OVESNÁ (203 Česká republika, domácí), Markéta BEDNAŘÍKOVÁ (203 Česká republika, domácí), Luboš MINÁŘ (203 Česká republika, domácí), Michal FELSINGER (203 Česká republika, domácí), Jitka HAUSNEROVÁ (203 Česká republika, domácí) a Vít WEINBERGER (203 Česká republika, garant, domácí).
Vydání Cancers, Basel, MDPI, 2022, 2072-6694.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.200
Kód RIV RIV/00216224:14110/22:00125126
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/cancers14010115
UT WoS 000741365900001
Klíčová slova anglicky endometrial cancer; postmenopausal bleeding; prognosis
Štítky 14110212, 14110230, 14110411, 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 19. 7. 2022 09:29.
Anotace
Background: Endometrial cancer is the most common gynecological malignancy in developed countries with no screening available. There is still a tendency to provide invasive bioptic verification in asymptomatic women with abnormal ultrasound findings to diagnose carcinoma in a preclinical phase; even though, it is not supported by European guidelines. Our goal was to determine DFS (disease-free survival), OS (overall survival), and DSS (disease-specific survival) differences between symptom-free and symptomatic (bleeding, or spotting) endometrial cancer patients with similar stage and tumor/clinical characteristics. Methods: All of our patients with endometrial cancer following surgical treatment between 2006 and 2019 were assessed, evaluating risk factors for recurrence and death while focusing on bleeding using univariable and multivariable analysis. Results: 625 patients meeting the inclusion criteria were divided into asymptomatic (n = 144, 23%) and symptomatic (n = 481, 77%) groups. The median follow-up was 3.6 years. Using univariable analysis, symptomatic patients had a three times higher risk of recurrence (HR 3.1 (95% Cl 1.24–7.77), p = 0.016). OS (HR 1.35 (0.84–2.19), p = 0.219) and DSS (HR 1.66 (0.64–4.28), p = 0.3) were slightly worse without reaching statistical significance. In our multivariable analysis, symptomatology was deemed completely insignificant in all monitored parameters (DFS: HR 2.03 (0.79–5.24), p = 0.144; OS: HR 0.72 (0.43–1.21), p = 0.216). Conclusions: The symptomatic endometrial cancer patients risk factor of earlier recurrence and death is insignificantly higher when compared with the asymptomatic cohort. However, multivariable analysis verifies that prognosis worsens with other clinically relevant parameters, not by symptomatology itself. In terms of survival outcome in EC patients, we recognized symptomatology as a non-significant marker for the patient’s prognosis.
VytisknoutZobrazeno: 26. 4. 2024 03:12